A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
J. Glaspy et al., A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy, BR J CANC, 84, 2001, pp. 17-23
Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), whic
h stimulates erythropoiesis by the same mechanism as recombinant human eryt
hropoietin (rHuEPO). NESP has been shown to be safe and efficacious in pati
ents with chronic renal failure. NESP is biochemically distinct from FHuEPO
, due to its increased sialic acid content. NESP has an approximately 3-fol
d greater half-life, rHuEPO has been shown to be safe and effective for the
treatment of chemotherapy-induced anaemia. This study assessed the safety
and efficacy of NESP administered once per week, under the supervision of a
physician, to patients with solid tumours who were receiving multicycle ch
emotherapy for up to 12 weeks. Three dose cohorts are presented in this seq
uential, unblinded and dose-escalating study. Thirteen to 59 patients recei
ved NESP (0.5, 1.5 or 2.25 mcg kg(-1) wk(-1)) in each cohort, Patients were
monitored for adverse events? including antibody formation to NESP and for
effects on haemoglobin. NESP appeared to be well tolerated. Adverse events
were similar across all cohorts and were consistent with the population be
ing studied. No antibody formation was detected over the 16-week study peri
od and follow-up, A dose-response relationship was evident for NESP and mul
tiple measures of efficacy, including proportion of patients responding to
NESP and the mean change in haemoglobin by week 4 and end of treatment for
NESP 0.5, 1.5 and 2.25 meg kg(-1) wk(-1) cohorts (mean change in haemoglobi
n at end of treatment was 1.24, 1.73 and 2.15 g dl(-1) respectively). Contr
olled studies of this agent at higher doses and less frequent schedules of
administration are ongoing. (C) 2001 Cancer Research Campaign.